FDA Intends to Strengthen Recall Effectiveness Checks
Executive Summary
McKinsey & Co. submitted its Recall Business Process Improvement Study to FDA last year and delivered its recommendations this April.
You may also be interested in...
Drug Recalls Will Be Announced Without Classification Under FDA Pilot
FDA is pilot testing a program to speed notification of health care providers and patients about drug recalls.
Drug GMP Warning Letters, Enforcement Could Rebound in Obama's FDA
Reversal of downward enforcement trend expected after President Obama's team takes reins at FDA. After eight years of declining inspection activity, field staffing and warning letter issuance, industry is bracing for change. Obama demands "full review" of FDA over peanut recall. More criminal prosecutions expected. Congress plies agency with money for overseas inspections. FDA headquarters could unleash warning letters. New investigators will learn domestically while seasoned ones retire or head overseas. Focus of warning letters begins shifting abroad. Form 483 reports and warning letters continue to raise the same key issues. Production record review, data integrity, process validation concerns highlighted. Issues raised in 18 FY 2008 drug GMP warning letters detailed in chart beginning on page 12.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.